Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyOlsalazine
Identification
- Name
- Olsalazine
- Accession Number
- DB01250
- Type
- Small Molecule
- Groups
- Approved
- Description
Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.
- Structure
Structure for DB01250 (Olsalazine)
- Synonyms
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Olsalazine sodium Y7JEW0XG7I 6054-98-4 QQWFSVYVHLECFP-XBPUGJBTSA-L - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Dipentum Capsule, gelatin coated 250 mg/1 Oral Carilion Materials Management 1990-07-31 Not applicable US 
Dipentum Capsule 250 mg Oral Atnahs Pharma Uk Limited 1995-12-31 Not applicable Canada 
Dipentum Capsule, gelatin coated 250 mg/1 Oral Carilion Materials Management 2015-05-15 Not applicable US Dipentum Capsule, gelatin coated 250 mg/1 Oral Alaven Pharmaceutical 1990-07-31 2018-04-05 US Dipentum Capsule, gelatin coated 250 mg/1 Oral Meda Pharmaceuticals Ltd 2015-05-15 Not applicable US - International/Other Brands
- Dipentum
- Categories
- Acids, Carbocyclic
- Alimentary Tract and Metabolism
- Aminosalicylate
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Gastrointestinal Agents
- Hydroxy Acids
- Hydroxybenzoates
- Intestinal Antiinflammatory Agents
- Nephrotoxic agents
- Peripheral Nervous System Agents
- Phenols
- Salicylates
- Sensory System Agents
- UNII
- ULS5I8J03O
- CAS number
- 15722-48-2
- Weight
- Average: 302.239
Monoisotopic: 302.053886062 - Chemical Formula
- C14H10N2O6
- InChI Key
- QQBDLJCYGRGAKP-FOCLMDBBSA-N
- InChI
- InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+
- IUPAC Name
- 5-[(E)-2-(3-carboxy-4-hydroxyphenyl)diazen-1-yl]-2-hydroxybenzoic acid
- SMILES
- OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O
Pharmacology
- Indication
For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.
- Associated Conditions
- Pharmacodynamics
Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis.
- Mechanism of action
Orally administered olsalazine is converted to mesalamine which is thought to be the therapeutically active agent in the treatment of ulcerative colitis. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyelcosatetraenoic acids (HETEs) is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.
Target Actions Organism AThiopurine S-methyltransferase inhibitorHuman AInterferon gamma Not Available Human - Absorption
After oral administration, olsalazine, has limited systemic bioavailability. 98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.
- Volume of distribution
- Not Available
- Protein binding
Olsalazine and olsalazine-S are more than 99% bound to plasma proteins. Mesalamine (5-ASA) is 74% bound to plasma proteins.
- Metabolism
Most (98 to 99%) of an oral dose is rapidly converted into two molecules of 5-aminosalicylic acid (5-ASA) by colonic bacteria and the low prevailing redox potential found in this environment. The conversion of olsalazine to mesalamine in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S)
- Route of elimination
Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S).The remaining 5-ASA is partially acetylated and is excreted in the feces.
- Half life
Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.
- Clearance
- Not Available
- Toxicity
Maximum single oral doses of 5g/kg in mice and rats and 2 g/kg in dogs were not lethal.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the nephrotoxic activities of Olsalazine. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Olsalazine is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Olsalazine is combined with 5-androstenedione. Experimental, Illicit Abciximab Olsalazine may increase the anticoagulant activities of Abciximab. Approved Acarbose Olsalazine may increase the hypoglycemic activities of Acarbose. Approved, Investigational Acebutolol Olsalazine may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Olsalazine is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Olsalazine is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Olsalazine may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetazolamide The risk or severity of adverse effects can be increased when Olsalazine is combined with Acetazolamide. Approved, Vet Approved Acetyldigitoxin The serum concentration of Acetyldigitoxin can be decreased when it is combined with Olsalazine. Approved Acetyldigoxin The serum concentration of Acetyldigoxin can be decreased when it is combined with Olsalazine. Experimental Acetylsalicylic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Acetylsalicylic acid. Approved, Vet Approved Adapalene Adapalene may increase the nephrotoxic activities of Olsalazine. Approved Albiglutide Olsalazine may increase the hypoglycemic activities of Albiglutide. Approved Alclofenac Alclofenac may increase the nephrotoxic activities of Olsalazine. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Olsalazine is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid. Approved Aliskiren Olsalazine may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen Alminoprofen may increase the nephrotoxic activities of Olsalazine. Experimental Alogliptin Olsalazine may increase the hypoglycemic activities of Alogliptin. Approved Aloxiprin The risk or severity of adverse effects can be increased when Olsalazine is combined with Aloxiprin. Experimental Alprenolol Olsalazine may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Olsalazine. Approved, Investigational Alteplase The risk or severity of adverse effects can be increased when Olsalazine is combined with Alteplase. Approved Amcinonide The risk or severity of adverse effects can be increased when Olsalazine is combined with Amcinonide. Approved Amikacin Olsalazine may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Investigational, Vet Approved Amiloride Olsalazine may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Aminosalicylic Acid. Approved Amlodipine The therapeutic efficacy of Amlodipine can be decreased when used in combination with Olsalazine. Approved Ammonium chloride The serum concentration of Olsalazine can be increased when it is combined with Ammonium chloride. Approved, Investigational, Vet Approved Anagrelide The risk or severity of adverse effects can be increased when Anagrelide is combined with Olsalazine. Approved Ancrod Olsalazine may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide Andrographolide may increase the nephrotoxic activities of Olsalazine. Investigational Androstenedione The risk or severity of adverse effects can be increased when Olsalazine is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Olsalazine is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Olsalazine is combined with anecortave acetate. Investigational Anisodamine Anisodamine may increase the nephrotoxic activities of Olsalazine. Investigational Anistreplase The risk or severity of adverse effects can be increased when Olsalazine is combined with Anistreplase. Approved Antipyrine The risk or severity of adverse effects can be increased when Olsalazine is combined with Antipyrine. Approved, Investigational Antithrombin III human Olsalazine may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Olsalazine is combined with Antrafenine. Approved Apixaban Olsalazine may increase the anticoagulant activities of Apixaban. Approved Apocynin Apocynin may increase the nephrotoxic activities of Olsalazine. Investigational Apramycin Olsalazine may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast Apremilast may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Arbekacin Olsalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Olsalazine may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Olsalazine may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Olsalazine may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Olsalazine may decrease the antihypertensive activities of Asenapine. Approved Astaxanthin The risk or severity of adverse effects can be increased when Olsalazine is combined with Astaxanthin. Investigational Atamestane The risk or severity of adverse effects can be increased when Olsalazine is combined with Atamestane. Investigational Atenolol Olsalazine may decrease the antihypertensive activities of Atenolol. Approved Azapropazone Azapropazone may increase the nephrotoxic activities of Olsalazine. Withdrawn Azathioprine The metabolism of Azathioprine can be decreased when combined with Olsalazine. Approved Azelastine Azelastine may increase the nephrotoxic activities of Olsalazine. Approved Azficel-T The risk or severity of adverse effects can be increased when Olsalazine is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olsalazine. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Olsalazine. Investigational Bacitracin The risk or severity of nephrotoxicity can be increased when Olsalazine is combined with Bacitracin. Approved, Vet Approved Balsalazide The risk or severity of adverse effects can be increased when Olsalazine is combined with Balsalazide. Approved, Investigational Batroxobin The risk or severity of adverse effects can be increased when Olsalazine is combined with Batroxobin. Experimental Becaplermin Olsalazine may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Olsalazine is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Olsalazine may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Olsalazine may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Bemiparin The risk or severity of adverse effects can be increased when Olsalazine is combined with Bemiparin. Approved, Investigational Benazepril The risk or severity of adverse effects can be increased when Olsalazine is combined with Benazepril. Approved, Investigational Bendazac Bendazac may increase the nephrotoxic activities of Olsalazine. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine. Approved Benorilate Benorilate may increase the nephrotoxic activities of Olsalazine. Experimental Benoxaprofen Benoxaprofen may increase the nephrotoxic activities of Olsalazine. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Olsalazine. Approved Benzydamine Benzydamine may increase the nephrotoxic activities of Olsalazine. Approved Bepridil The therapeutic efficacy of Bepridil can be decreased when used in combination with Olsalazine. Approved, Withdrawn Beraprost The risk or severity of adverse effects can be increased when Beraprost is combined with Olsalazine. Investigational Betamethasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Betamethasone. Approved, Vet Approved Betaxolol Olsalazine may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Olsalazine. Approved, Investigational Bevantolol Olsalazine may decrease the antihypertensive activities of Bevantolol. Approved Bevonium Bevonium may increase the nephrotoxic activities of Olsalazine. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olsalazine. Approved, Investigational Bisoprolol Olsalazine may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Olsalazine may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Olsalazine may decrease the antihypertensive activities of Bopindolol. Approved Brinase The risk or severity of adverse effects can be increased when Olsalazine is combined with Brinase. Experimental Brinzolamide The risk or severity of adverse effects can be increased when Olsalazine is combined with Brinzolamide. Approved Bromfenac The risk or severity of adverse effects can be increased when Olsalazine is combined with Bromfenac. Approved Bromocriptine Olsalazine may increase the hypoglycemic activities of Bromocriptine. Approved, Investigational Bucillamine Bucillamine may increase the nephrotoxic activities of Olsalazine. Investigational Bucindolol Olsalazine may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Olsalazine is combined with Bufexamac. Approved, Experimental Buflomedil The risk or severity of adverse effects can be increased when Buflomedil is combined with Olsalazine. Experimental Bufuralol Olsalazine may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone Bumadizone may increase the nephrotoxic activities of Olsalazine. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Olsalazine. Approved Bupranolol Olsalazine may decrease the antihypertensive activities of Bupranolol. Approved Butylphthalide The risk or severity of adverse effects can be increased when Butylphthalide is combined with Olsalazine. Investigational Canagliflozin Olsalazine may increase the hypoglycemic activities of Canagliflozin. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Olsalazine. Approved Candoxatril The risk or severity of adverse effects can be increased when Olsalazine is combined with Candoxatril. Experimental Cangrelor The risk or severity of adverse effects can be increased when Cangrelor is combined with Olsalazine. Approved Caplacizumab The risk or severity of adverse effects can be increased when Olsalazine is combined with Caplacizumab. Investigational Capsaicin The risk or severity of adverse effects can be increased when Olsalazine is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Olsalazine is combined with Captopril. Approved Carbaspirin calcium Carbaspirin calcium may increase the nephrotoxic activities of Olsalazine. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olsalazine. Approved Carprofen The risk or severity of adverse effects can be increased when Olsalazine is combined with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Olsalazine may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Olsalazine may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine Castanospermine may increase the nephrotoxic activities of Olsalazine. Experimental Celecoxib The risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib. Approved, Investigational Celiprolol Olsalazine may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Olsalazine may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine Chloroquine may increase the nephrotoxic activities of Olsalazine. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine. Approved, Vet Approved Chlorphenesin The risk or severity of adverse effects can be increased when Olsalazine is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorpropamide Olsalazine may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olsalazine. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Olsalazine is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Olsalazine is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Olsalazine is combined with Cilazapril. Approved Cilostazol The risk or severity of adverse effects can be increased when Cilostazol is combined with Olsalazine. Approved, Investigational Cimicoxib The risk or severity of adverse effects can be increased when Olsalazine is combined with Cimicoxib. Investigational Cinoxacin Olsalazine may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin Olsalazine may increase the neuroexcitatory activities of Ciprofloxacin. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when Olsalazine is combined with Cisplatin. Approved Clobetasol The risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin Clonixin may increase the nephrotoxic activities of Olsalazine. Approved Clopidogrel The risk or severity of adverse effects can be increased when Clopidogrel is combined with Olsalazine. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olsalazine. Vet Approved Cloranolol Olsalazine may decrease the antihypertensive activities of Cloranolol. Experimental Cloricromen The risk or severity of adverse effects can be increased when Cloricromen is combined with Olsalazine. Experimental Clorindione Olsalazine may increase the anticoagulant activities of Clorindione. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Olsalazine is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Olsalazine is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Olsalazine is combined with Cortisone acetate. Approved, Investigational Curcumin Curcumin may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Olsalazine. Experimental Cyclosporine The risk or severity of renal failure and hypertension can be increased when Olsalazine is combined with Cyclosporine. Approved, Investigational, Vet Approved Cymarin The serum concentration of Cymarin can be decreased when it is combined with Olsalazine. Experimental Dabigatran etexilate Olsalazine may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Olsalazine may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Olsalazine may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Dapagliflozin Olsalazine may increase the hypoglycemic activities of Dapagliflozin. Approved Darexaban Olsalazine may increase the anticoagulant activities of Darexaban. Investigational Deferasirox The risk or severity of adverse effects can be increased when Olsalazine is combined with Deferasirox. Approved, Investigational Defibrotide The risk or severity of adverse effects can be increased when Defibrotide is combined with Olsalazine. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Olsalazine is combined with Deflazacort. Approved, Investigational Delapril The therapeutic efficacy of Delapril can be decreased when used in combination with Olsalazine. Investigational Dersalazine Olsalazine may increase the anticoagulant activities of Dersalazine. Investigational Desipramine Olsalazine may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Olsalazine may increase the anticoagulant activities of Desirudin. Approved Deslanoside The serum concentration of Deslanoside can be decreased when it is combined with Olsalazine. Approved Desmopressin The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin. Approved Desmoteplase The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmoteplase. Investigational Desonide The risk or severity of adverse effects can be increased when Olsalazine is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Olsalazine is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olsalazine. Approved, Investigational Dexniguldipine The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Olsalazine. Experimental Dextran Olsalazine may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin Olsalazine may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Olsalazine is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Olsalazine. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Olsalazine is combined with Diclofenamide. Approved, Investigational Dicoumarol Olsalazine may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide Difenpiramide may increase the nephrotoxic activities of Olsalazine. Experimental Diflorasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Olsalazine is combined with Diflunisal. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Olsalazine is combined with Difluprednate. Approved Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Olsalazine. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Olsalazine. Approved Digoxin Immune Fab (Ovine) The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Olsalazine. Approved Dihydrostreptomycin Olsalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Diltiazem Diltiazem may increase the anticoagulant activities of Olsalazine. Approved, Investigational Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Olsalazine. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olsalazine. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olsalazine. Approved Diphenadione Olsalazine may increase the anticoagulant activities of Diphenadione. Experimental Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Olsalazine. Approved Disopyramide Olsalazine may increase the hypoglycemic activities of Disopyramide. Approved Ditazole The risk or severity of adverse effects can be increased when Olsalazine is combined with Ditazole. Approved, Withdrawn Dorzolamide The risk or severity of adverse effects can be increased when Olsalazine is combined with Dorzolamide. Approved Doxazosin The therapeutic efficacy of Doxazosin can be decreased when used in combination with Olsalazine. Approved Drospirenone Olsalazine may increase the hyperkalemic activities of Drospirenone. Approved Drotrecogin alfa The risk or severity of adverse effects can be increased when Olsalazine is combined with Drotrecogin alfa. Approved, Investigational, Withdrawn Droxicam The risk or severity of adverse effects can be increased when Olsalazine is combined with Droxicam. Withdrawn Dulaglutide Olsalazine may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Duvelisib Duvelisib may increase the nephrotoxic activities of Olsalazine. Investigational E-6201 E-6201 may increase the nephrotoxic activities of Olsalazine. Investigational Edetic Acid Olsalazine may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Olsalazine may increase the anticoagulant activities of Edoxaban. Approved Efonidipine The therapeutic efficacy of Efonidipine can be decreased when used in combination with Olsalazine. Approved, Investigational Empagliflozin Olsalazine may increase the hypoglycemic activities of Empagliflozin. Approved Enalapril The risk or severity of adverse effects can be increased when Olsalazine is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Olsalazine is combined with Enalaprilat. Approved Enoxacin Olsalazine may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Olsalazine may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Olsalazine. Experimental Epanolol Olsalazine may decrease the antihypertensive activities of Epanolol. Experimental Epinastine The risk or severity of adverse effects can be increased when Epinastine is combined with Olsalazine. Approved, Investigational Epirizole Epirizole may increase the nephrotoxic activities of Olsalazine. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Olsalazine. Experimental Eplerenone Olsalazine may decrease the antihypertensive activities of Eplerenone. Approved Eplivanserin The risk or severity of adverse effects can be increased when Eplivanserin is combined with Olsalazine. Investigational Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine. Approved Eptifibatide The risk or severity of adverse effects can be increased when Eptifibatide is combined with Olsalazine. Approved, Investigational Equilenin The risk or severity of adverse effects can be increased when Olsalazine is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Olsalazine is combined with Equilin. Approved Esatenolol Olsalazine may decrease the antihypertensive activities of Esatenolol. Experimental Esmolol Olsalazine may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Olsalazine. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Olsalazine is combined with Etanercept. Approved, Investigational Ethenzamide Ethenzamide may increase the nephrotoxic activities of Olsalazine. Experimental Ethoxzolamide The risk or severity of adverse effects can be increased when Olsalazine is combined with Ethoxzolamide. Withdrawn Ethyl biscoumacetate Olsalazine may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Olsalazine is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib. Approved, Investigational Evening primrose oil Evening primrose oil may increase the nephrotoxic activities of Olsalazine. Investigational, Nutraceutical Exenatide Olsalazine may increase the hypoglycemic activities of Exenatide. Approved, Investigational Exisulind Exisulind may increase the nephrotoxic activities of Olsalazine. Investigational Felbinac Felbinac may increase the nephrotoxic activities of Olsalazine. Experimental Felodipine The therapeutic efficacy of Felodipine can be decreased when used in combination with Olsalazine. Approved, Investigational Fenbufen Fenbufen may increase the nephrotoxic activities of Olsalazine. Approved Fenoprofen The risk or severity of adverse effects can be increased when Olsalazine is combined with Fenoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Olsalazine. Vet Approved Fentiazac Fentiazac may increase the nephrotoxic activities of Olsalazine. Experimental Feprazone Feprazone may increase the nephrotoxic activities of Olsalazine. Experimental Ferulic acid Ferulic acid may increase the nephrotoxic activities of Olsalazine. Experimental Fibrinolysin The risk or severity of adverse effects can be increased when Olsalazine is combined with Fibrinolysin. Investigational Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Olsalazine. Approved, Investigational Fleroxacin Olsalazine may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Olsalazine. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Olsalazine is combined with Fludrocortisone. Approved, Investigational Fluindione Olsalazine may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Olsalazine may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Olsalazine is combined with Flunisolide. Approved, Investigational Flunixin Flunixin may increase the nephrotoxic activities of Olsalazine. Vet Approved Flunoxaprofen Flunoxaprofen may increase the nephrotoxic activities of Olsalazine. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Olsalazine. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Olsalazine is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Olsalazine is combined with Flurbiprofen. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone propionate. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Olsalazine. Approved, Nutraceutical, Vet Approved Fondaparinux Olsalazine may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Olsalazine. Experimental Formestane The risk or severity of adverse effects can be increased when Olsalazine is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Olsalazine is combined with Fosinopril. Approved Framycetin Olsalazine may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Olsalazine. Approved, Vet Approved Gabexate Olsalazine may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Olsalazine may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Olsalazine may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Olsalazine. Approved, Withdrawn Gemifloxacin Olsalazine may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Olsalazine may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Olsalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Olsalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Olsalazine. Approved, Investigational, Nutraceutical Ginseng The risk or severity of adverse effects can be increased when Olsalazine is combined with Ginseng. Approved, Investigational, Nutraceutical Gitoformate The serum concentration of Gitoformate can be decreased when it is combined with Olsalazine. Experimental Gliclazide Olsalazine may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Olsalazine may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Olsalazine may increase the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Olsalazine may increase the hypoglycemic activities of Glyburide. Approved Grepafloxacin Olsalazine may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal Guacetisal may increase the nephrotoxic activities of Olsalazine. Experimental Guanfacine The therapeutic efficacy of Guanfacine can be decreased when used in combination with Olsalazine. Approved, Investigational Halcinonide The risk or severity of adverse effects can be increased when Olsalazine is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Olsalazine is combined with HE3286. Investigational Hemoglobin crosfumaril Olsalazine may increase the anticoagulant activities of Hemoglobin crosfumaril. Experimental Heparin The risk or severity of adverse effects can be increased when Olsalazine is combined with Heparin. Approved, Investigational Higenamine Higenamine may increase the nephrotoxic activities of Olsalazine. Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olsalazine. Approved, Investigational Hydralazine Olsalazine may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone. Approved, Vet Approved Hydrocortisone acetate The risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone acetate. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olsalazine. Approved, Investigational Hydroxytyrosol The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Olsalazine. Investigational Hygromycin B Olsalazine may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate. Approved, Investigational Ibudilast The risk or severity of adverse effects can be increased when Ibudilast is combined with Olsalazine. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Olsalazine. Approved Ibuproxam Ibuproxam may increase the nephrotoxic activities of Olsalazine. Withdrawn Icatibant Icatibant may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Olsalazine is combined with Icosapent. Approved, Nutraceutical Icosapent ethyl The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Olsalazine. Approved, Investigational, Nutraceutical Idraparinux Olsalazine may increase the anticoagulant activities of Idraparinux. Investigational Ifenprodil The risk or severity of adverse effects can be increased when Ifenprodil is combined with Olsalazine. Approved, Investigational, Withdrawn Ifetroban The risk or severity of adverse effects can be increased when Ifetroban is combined with Olsalazine. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Olsalazine is combined with Imidapril. Investigational Imidazole salicylate Imidazole salicylate may increase the nephrotoxic activities of Olsalazine. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine. Approved Indenolol Olsalazine may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Olsalazine is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Olsalazine is combined with Indomethacin. Approved, Investigational Indoprofen Indoprofen may increase the nephrotoxic activities of Olsalazine. Withdrawn Insulin Aspart Olsalazine may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Olsalazine may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Olsalazine may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Olsalazine may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Olsalazine may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Olsalazine may increase the hypoglycemic activities of Insulin Lispro. Approved Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine. Approved, Investigational Isepamicin Olsalazine may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam Isoxicam may increase the nephrotoxic activities of Olsalazine. Withdrawn Isradipine The therapeutic efficacy of Isradipine can be decreased when used in combination with Olsalazine. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Olsalazine is combined with Istaroxime. Investigational Kanamycin Olsalazine may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone Kebuzone may increase the nephrotoxic activities of Olsalazine. Experimental Ketanserin The risk or severity of adverse effects can be increased when Ketanserin is combined with Olsalazine. Investigational Ketoprofen The risk or severity of adverse effects can be increased when Olsalazine is combined with Ketoprofen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Olsalazine. Approved Labetalol Olsalazine may decrease the antihypertensive activities of Labetalol. Approved Lacidipine The therapeutic efficacy of Lacidipine can be decreased when used in combination with Olsalazine. Approved, Investigational Lanatoside C The serum concentration of Lanatoside C can be decreased when it is combined with Olsalazine. Experimental Landiolol Olsalazine may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Olsalazine. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Olsalazine. Approved, Investigational Leflunomide Leflunomide may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Lepirudin Olsalazine may increase the anticoagulant activities of Lepirudin. Approved Lercanidipine The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Olsalazine. Approved, Investigational Letaxaban Olsalazine may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol Olsalazine may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Olsalazine may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Olsalazine may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Olsalazine. Approved, Investigational Linsidomine The risk or severity of adverse effects can be increased when Linsidomine is combined with Olsalazine. Experimental Liraglutide Olsalazine may increase the hypoglycemic activities of Liraglutide. Approved Lisinopril The risk or severity of adverse effects can be increased when Olsalazine is combined with Lisinopril. Approved, Investigational Lisofylline Lisofylline may increase the nephrotoxic activities of Olsalazine. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Olsalazine. Experimental Lomefloxacin Olsalazine may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac Lonazolac may increase the nephrotoxic activities of Olsalazine. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Olsalazine is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Olsalazine. Approved Loteprednol The risk or severity of adverse effects can be increased when Olsalazine is combined with Loteprednol. Approved Loxoprofen Loxoprofen may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olsalazine. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Olsalazine is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Olsalazine. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Olsalazine is combined with Magnesium salicylate. Approved Manidipine The therapeutic efficacy of Manidipine can be decreased when used in combination with Olsalazine. Approved, Investigational Masoprocol Masoprocol may increase the nephrotoxic activities of Olsalazine. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Olsalazine is combined with ME-609. Investigational Mecasermin Olsalazine may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Meclofenamic acid. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Olsalazine is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Mefenamic acid. Approved Melagatran Olsalazine may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Olsalazine is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Olsalazine is combined with Meloxicam. Approved, Vet Approved Mepindolol Olsalazine may decrease the antihypertensive activities of Mepindolol. Experimental Mercaptopurine The metabolism of Mercaptopurine can be decreased when combined with Olsalazine. Approved Mesalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Mesalazine. Approved Metamizole Metamizole may increase the nephrotoxic activities of Olsalazine. Approved, Investigational, Withdrawn Metformin Olsalazine may increase the hypoglycemic activities of Metformin. Approved Methazolamide The risk or severity of adverse effects can be increased when Olsalazine is combined with Methazolamide. Approved Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Olsalazine. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine. Approved Methyl salicylate The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Olsalazine is combined with Methyl salicylate. Approved, Vet Approved Methylprednisolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Methylprednisolone. Approved, Vet Approved Metildigoxin The serum concentration of Metildigoxin can be decreased when it is combined with Olsalazine. Experimental Metipranolol Olsalazine may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine. Approved Metoprolol Olsalazine may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Mibefradil The therapeutic efficacy of Mibefradil can be decreased when used in combination with Olsalazine. Investigational, Withdrawn Micronomicin Olsalazine may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Olsalazine. Approved, Experimental Mifepristone Olsalazine may increase the hypoglycemic activities of Mifepristone. Approved, Investigational Miglitol Olsalazine may increase the hypoglycemic activities of Miglitol. Approved Milrinone The risk or severity of adverse effects can be increased when Milrinone is combined with Olsalazine. Approved Minoxidil The therapeutic efficacy of Minoxidil can be decreased when used in combination with Olsalazine. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Olsalazine. Approved Mizoribine Mizoribine may increase the nephrotoxic activities of Olsalazine. Investigational Moexipril The risk or severity of adverse effects can be increased when Olsalazine is combined with Moexipril. Approved Mofebutazone Mofebutazone may increase the nephrotoxic activities of Olsalazine. Experimental Mometasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Olsalazine. Approved Moxifloxacin Olsalazine may increase the neuroexcitatory activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil Mycophenolate mofetil may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Mycophenolic acid Mycophenolic acid may increase the nephrotoxic activities of Olsalazine. Approved Nabumetone The risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone. Approved Nadolol Olsalazine may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Olsalazine may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Nafamostat may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Naftifine Naftifine may increase the nephrotoxic activities of Olsalazine. Approved Naftopidil The risk or severity of adverse effects can be increased when Naftopidil is combined with Olsalazine. Investigational Nalidixic Acid Olsalazine may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Olsalazine. Approved, Vet Approved Nateglinide Olsalazine may increase the hypoglycemic activities of Nateglinide. Approved, Investigational NCX 1022 The risk or severity of adverse effects can be increased when Olsalazine is combined with NCX 1022. Investigational Neamine Olsalazine may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Olsalazine may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Olsalazine may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin The risk or severity of nephrotoxicity can be increased when Olsalazine is combined with Neomycin. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Olsalazine is combined with Nepafenac. Approved, Investigational Netilmicin Olsalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Olsalazine. Approved, Investigational Nifenazone Nifenazone may increase the nephrotoxic activities of Olsalazine. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Niflumic Acid. Approved Niguldipine The therapeutic efficacy of Niguldipine can be decreased when used in combination with Olsalazine. Experimental Nilvadipine The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Olsalazine. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Olsalazine is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The therapeutic efficacy of Nimodipine can be decreased when used in combination with Olsalazine. Approved, Investigational Nisoldipine The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Olsalazine. Approved Nitrendipine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Olsalazine. Approved, Investigational Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Olsalazine. Investigational Norfloxacin Olsalazine may increase the neuroexcitatory activities of Norfloxacin. Approved Ofloxacin Olsalazine may increase the neuroexcitatory activities of Ofloxacin. Approved Oleandrin The serum concentration of Oleandrin can be decreased when it is combined with Olsalazine. Experimental, Investigational Oleoyl-estrone The risk or severity of adverse effects can be increased when Olsalazine is combined with Oleoyl-estrone. Investigational Olopatadine Olopatadine may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Olsalazine is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Olsalazine is combined with Omapatrilat. Investigational Orgotein Orgotein may increase the nephrotoxic activities of Olsalazine. Vet Approved Otamixaban Olsalazine may increase the anticoagulant activities of Otamixaban. Investigational Ouabain The serum concentration of Ouabain can be decreased when it is combined with Olsalazine. Approved Oxaprozin The risk or severity of adverse effects can be increased when Olsalazine is combined with Oxaprozin. Approved Oxolinic acid Olsalazine may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Olsalazine may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone Oxyphenbutazone may increase the nephrotoxic activities of Olsalazine. Approved, Withdrawn Ozagrel The risk or severity of adverse effects can be increased when Olsalazine is combined with Ozagrel. Investigational Palmidrol Palmidrol may increase the nephrotoxic activities of Olsalazine. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when Olsalazine is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Olsalazine is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Olsalazine is combined with Parecoxib. Approved Parnaparin The risk or severity of adverse effects can be increased when Olsalazine is combined with Parnaparin. Approved, Investigational Paromomycin Olsalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Parthenolide Parthenolide may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Pazufloxacin Olsalazine may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Olsalazine may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Olsalazine may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Olsalazine may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentamidine Olsalazine may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Pentosan Polysulfate Olsalazine may increase the anticoagulant activities of Pentosan Polysulfate. Approved Pentoxifylline The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Olsalazine. Approved, Investigational Perindopril The risk or severity of adverse effects can be increased when Olsalazine is combined with Perindopril. Approved Peruvoside The serum concentration of Peruvoside can be decreased when it is combined with Olsalazine. Experimental Phenindione Olsalazine may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Olsalazine may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenyl aminosalicylate Olsalazine may increase the anticoagulant activities of Phenyl aminosalicylate. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Olsalazine is combined with Phenylbutazone. Approved, Vet Approved Picotamide The risk or severity of adverse effects can be increased when Picotamide is combined with Olsalazine. Experimental Pimecrolimus Pimecrolimus may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Pindolol Olsalazine may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pioglitazone Olsalazine may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pipemidic acid Olsalazine may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Olsalazine. Approved Pirfenidone Pirfenidone may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Piromidic acid Olsalazine may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Olsalazine is combined with Piroxicam. Approved, Investigational Pirprofen Pirprofen may increase the nephrotoxic activities of Olsalazine. Experimental Pitolisant The risk or severity of adverse effects can be increased when Olsalazine is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Olsalazine may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Olsalazine may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Olsalazine. Approved Pomalidomide The risk or severity of adverse effects can be increased when Olsalazine is combined with Pomalidomide. Approved Potassium Citrate Olsalazine may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Olsalazine may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Olsalazine. Approved, Investigational Pramlintide Olsalazine may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Pranoprofen Pranoprofen may increase the nephrotoxic activities of Olsalazine. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone sulfate. Investigational Prasugrel The risk or severity of adverse effects can be increased when Prasugrel is combined with Olsalazine. Approved Prednicarbate The risk or severity of adverse effects can be increased when Olsalazine is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Olsalazine can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin Proglumetacin may increase the nephrotoxic activities of Olsalazine. Experimental Propacetamol Propacetamol may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Propafenone Olsalazine may decrease the antihypertensive activities of Propafenone. Approved Propranolol Olsalazine may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone Propyphenazone may increase the nephrotoxic activities of Olsalazine. Experimental Proquazone Proquazone may increase the nephrotoxic activities of Olsalazine. Experimental Proscillaridin The serum concentration of Proscillaridin can be decreased when it is combined with Olsalazine. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Olsalazine. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Olsalazine. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Olsalazine. Vet Approved Protein C Olsalazine may increase the anticoagulant activities of Protein C. Approved Protein S human Olsalazine may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Olsalazine may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Olsalazine may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 PTC299 may increase the nephrotoxic activities of Olsalazine. Investigational Puromycin Olsalazine may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Olsalazine is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Olsalazine. Approved Quinine Olsalazine may increase the hypoglycemic activities of Quinine. Approved Ramatroban The risk or severity of adverse effects can be increased when Ramatroban is combined with Olsalazine. Investigational Ramipril The risk or severity of adverse effects can be increased when Olsalazine is combined with Ramipril. Approved Relcovaptan The risk or severity of adverse effects can be increased when Relcovaptan is combined with Olsalazine. Investigational Repaglinide Olsalazine may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Rescinnamine The risk or severity of adverse effects can be increased when Olsalazine is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Olsalazine is combined with Resveratrol. Approved, Experimental, Investigational Reteplase The risk or severity of adverse effects can be increased when Olsalazine is combined with Reteplase. Approved, Investigational Reviparin Olsalazine may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Olsalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Ridogrel The risk or severity of adverse effects can be increased when Ridogrel is combined with Olsalazine. Approved Rimexolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate. Approved, Investigational Rivaroxaban Olsalazine may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Olsalazine is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosiglitazone Olsalazine may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Rosoxacin Olsalazine may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Olsalazine may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Olsalazine. Approved Salicylamide Salicylamide may increase the nephrotoxic activities of Olsalazine. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Olsalazine. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Olsalazine is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Olsalazine. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Olsalazine. Approved, Investigational Sarpogrelate The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Olsalazine. Investigational Saruplase The risk or severity of adverse effects can be increased when Olsalazine is combined with Saruplase. Experimental Saxagliptin Olsalazine may increase the hypoglycemic activities of Saxagliptin. Approved Selexipag The risk or severity of adverse effects can be increased when Olsalazine is combined with Selexipag. Approved Seliciclib The risk or severity of adverse effects can be increased when Olsalazine is combined with Seliciclib. Investigational Semapimod Semapimod may increase the nephrotoxic activities of Olsalazine. Investigational Seratrodast Seratrodast may increase the nephrotoxic activities of Olsalazine. Approved Serrapeptase Serrapeptase may increase the nephrotoxic activities of Olsalazine. Investigational Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Olsalazine. Approved, Vet Approved Sisomicin Olsalazine may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Olsalazine may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sitagliptin Olsalazine may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sodium Citrate The risk or severity of bleeding can be increased when Olsalazine is combined with Sodium Citrate. Approved, Investigational Sodium phosphate, monobasic The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Olsalazine. Approved Sotalol Olsalazine may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin Olsalazine may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Olsalazine is combined with Spirapril. Approved Spironolactone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olsalazine is combined with Spironolactone. Approved SRT501 SRT501 may increase the nephrotoxic activities of Olsalazine. Investigational Streptokinase The risk or severity of adverse effects can be increased when Olsalazine is combined with Streptokinase. Approved, Investigational Streptomycin Olsalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulfadiazine Olsalazine may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Olsalazine may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Olsalazine. Approved Sulfisoxazole Olsalazine may increase the hypoglycemic activities of Sulfisoxazole. Approved, Vet Approved Sulindac The risk or severity of adverse effects can be increased when Olsalazine is combined with Sulindac. Approved, Investigational Sulodexide Olsalazine may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Olsalazine. Investigational Sunitinib Olsalazine may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Olsalazine is combined with Suprofen. Approved, Withdrawn Suxibuzone Suxibuzone may increase the nephrotoxic activities of Olsalazine. Experimental Tacrolimus Olsalazine may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Olsalazine. Approved Talinolol Olsalazine may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Olsalazine. Approved Tarenflurbil Tarenflurbil may increase the nephrotoxic activities of Olsalazine. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Olsalazine. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine. Approved, Investigational Temafloxacin Olsalazine may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Olsalazine is combined with Temocapril. Experimental, Investigational Tenecteplase The risk or severity of adverse effects can be increased when Olsalazine is combined with Tenecteplase. Approved Tenidap Tenidap may increase the nephrotoxic activities of Olsalazine. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Olsalazine is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Olsalazine is combined with Tenoxicam. Approved Tepoxalin Tepoxalin may increase the nephrotoxic activities of Olsalazine. Vet Approved Terbutaline Olsalazine may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide Teriflunomide may increase the nephrotoxic activities of Olsalazine. Approved Tertatolol Olsalazine may decrease the antihypertensive activities of Tertatolol. Experimental Tesmilifene The risk or severity of adverse effects can be increased when Tesmilifene is combined with Olsalazine. Investigational Tetrahydropalmatine The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Olsalazine. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Tiaprofenic acid. Approved Ticagrelor The risk or severity of adverse effects can be increased when Olsalazine is combined with Ticagrelor. Approved Ticlopidine The risk or severity of adverse effects can be increased when Ticlopidine is combined with Olsalazine. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Olsalazine may decrease the antihypertensive activities of Timolol. Approved Tinoridine Tinoridine may increase the nephrotoxic activities of Olsalazine. Investigational Tinzaparin The risk or severity of adverse effects can be increased when Olsalazine is combined with Tinzaparin. Approved Tioclomarol Olsalazine may increase the anticoagulant activities of Tioclomarol. Experimental Tioguanine The metabolism of Tioguanine can be decreased when combined with Olsalazine. Approved Tirofiban The risk or severity of adverse effects can be increased when Tirofiban is combined with Olsalazine. Approved Tixocortol The risk or severity of adverse effects can be increased when Olsalazine is combined with Tixocortol. Approved, Withdrawn Tobramycin Olsalazine may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolazamide Olsalazine may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Olsalazine may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Olsalazine is combined with Tolmetin. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Olsalazine. Approved Trandolapril The risk or severity of adverse effects can be increased when Olsalazine is combined with Trandolapril. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Olsalazine. Approved, Investigational Trapidil The risk or severity of adverse effects can be increased when Trapidil is combined with Olsalazine. Approved Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Olsalazine is combined with Triamcinolone. Approved, Vet Approved Triamterene Olsalazine may decrease the antihypertensive activities of Triamterene. Approved Tribenoside Tribenoside may increase the nephrotoxic activities of Olsalazine. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olsalazine. Approved, Vet Approved Triflusal The risk or severity of adverse effects can be increased when Triflusal is combined with Olsalazine. Approved, Investigational Triptolide Triptolide may increase the nephrotoxic activities of Olsalazine. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Olsalazine is combined with Trolamine salicylate. Approved Trovafloxacin Olsalazine may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Olsalazine may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Olsalazine is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Olsalazine. Approved, Investigational Urokinase The risk or severity of adverse effects can be increased when Olsalazine is combined with Urokinase. Approved, Investigational, Withdrawn Valdecoxib The risk or severity of adverse effects can be increased when Olsalazine is combined with Valdecoxib. Approved, Investigational, Withdrawn Valproic Acid The serum concentration of Valproic Acid can be increased when it is combined with Olsalazine. Approved, Investigational Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Olsalazine. Approved Verapamil Verapamil may increase the anticoagulant activities of Olsalazine. Approved Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Olsalazine. Approved Warfarin Olsalazine may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Olsalazine may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen Zaltoprofen may increase the nephrotoxic activities of Olsalazine. Approved, Investigational Zileuton Zileuton may increase the nephrotoxic activities of Olsalazine. Approved, Investigational, Withdrawn Zofenopril The therapeutic efficacy of Zofenopril can be decreased when used in combination with Olsalazine. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Olsalazine is combined with Zoledronic acid. Approved Zomepirac Zomepirac may increase the nephrotoxic activities of Olsalazine. Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015380
- KEGG Drug
- D00727
- KEGG Compound
- C07323
- PubChem Compound
- 6003770
- PubChem Substance
- 46506356
- ChemSpider
- 10642377
- ChEMBL
- CHEMBL425
- PharmGKB
- PA450700
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Olsalazine
- ATC Codes
- A07EC03 — Olsalazine
- AHFS Codes
- 56:36.00 — Anti-inflammatory Agents
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Ankylosing Spondylitis (AS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Alaven Pharmaceutical
- Pfizer Inc.
- Pharmacia Inc.
- UCB Pharma
- Dosage forms
Form Route Strength Capsule Oral 250 mg Capsule, gelatin coated Oral 250 mg/1 - Prices
Unit description Cost Unit Dipentum 250 mg capsule 1.8USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Sodium salt decomposes at 240 °C Not Available logP 2.3 Not Available Caco2 permeability -6.96 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.0781 mg/mL ALOGPS logP 2.77 ALOGPS logP 4.39 ChemAxon logS -3.6 ALOGPS pKa (Strongest Acidic) 2.93 ChemAxon pKa (Strongest Basic) -0.019 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 139.78 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 78.85 m3·mol-1 ChemAxon Polarizability 28.61 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.8502 Blood Brain Barrier + 0.6279 Caco-2 permeable - 0.6449 P-glycoprotein substrate Non-substrate 0.7433 P-glycoprotein inhibitor I Non-inhibitor 0.8628 P-glycoprotein inhibitor II Non-inhibitor 0.9525 Renal organic cation transporter Non-inhibitor 0.8844 CYP450 2C9 substrate Non-substrate 0.7774 CYP450 2D6 substrate Non-substrate 0.8748 CYP450 3A4 substrate Non-substrate 0.6636 CYP450 1A2 substrate Non-inhibitor 0.8006 CYP450 2C9 inhibitor Non-inhibitor 0.7804 CYP450 2D6 inhibitor Non-inhibitor 0.9047 CYP450 2C19 inhibitor Non-inhibitor 0.8638 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8912 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.5546 Biodegradation Not ready biodegradable 0.8701 Rat acute toxicity 1.4882 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9506 hERG inhibition (predictor II) Non-inhibitor 0.9453
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azobenzenes
- Sub Class
- Not Available
- Direct Parent
- Azobenzenes
- Alternative Parents
- Salicylic acids / Benzoic acids / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Dicarboxylic acids and derivatives / Vinylogous acids / Azo compounds / Propargyl-type 1,3-dipolar organic compounds / Carboxylic acids / Organopnictogen compounds show 3 more
- Substituents
- Azobenzene / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Benzoic acid or derivatives / Benzoic acid / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Monocyclic benzene moiety show 16 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Thiopurine s-methyltransferase activity
- Specific Function
- Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
- Gene Name
- TPMT
- Uniprot ID
- P51580
- Uniprot Name
- Thiopurine S-methyltransferase
- Molecular Weight
- 28180.09 Da
References
- Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997 Oct;62(4):464-75. [PubMed:9357398]
- Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002 Aug;51(2):143-6. [PubMed:12117866]
- Lennard L: Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998 Oct;20(5):527-31. [PubMed:9780130]
- Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E: Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem. 2004 Feb;50(2):438-41. [PubMed:14752016]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- General Function
- Interferon-gamma receptor binding
- Specific Function
- Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrop...
- Gene Name
- IFNG
- Uniprot ID
- P01579
- Uniprot Name
- Interferon gamma
- Molecular Weight
- 19348.165 Da
References
- Egan LJ, Sandborn WJ: Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov;115(5):1295-6. [PubMed:9797390]
- Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, Kataoka K, Okanoue T, Mazda O: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006 Nov;146(2):330-8. [PubMed:17034586]
Drug created on March 30, 2007 06:25 / Updated on August 14, 2018 04:32